Japanese Drug Company Selects H&K
Charting the future of public relations
Holmes Report
CEO

Japanese Drug Company Selects H&K

The U.S. operation of Japan-based pharmaceutical company Eisai has selected Hill & Knowlton to plan and implement a strategic communications program to enhance the company’s visibility in this country.

Paul Holmes

  NEW YORK, August 22—The U.S. operation of Japan-based pharmaceutical company Eisai has selected Hill & Knowlton to plan and implement a strategic communications program to enhance the company’s visibility in this country.
 
  “Eisai chose Hill & Knowlton based on a proposal that fully addressed Eisai's corporate visibility needs and complemented Hill & Knowlton's ongoing campaigns for Eisai products,” according to Bill Sheldon president of Eisai.
 
The account team will draw on H&K’s expertise in health and pharmaceutical, media, corporate and financial communications. Hill & Knowlton has worked with Eisai since 1997, first on public relations for the world’s leading Alzheimer’s drug, Aricept, and beginning in 1999 on public relations activities for Aciphex, a drug treating gastrointestinal disorders.
View Style:

Load 3 More
comments powered by Disqus